



Monday 19 June 2023

## CHANGE OF REGISTERED OFFICE AND PRINCIPAL PLACE OF BUSINESS

In accordance with Listing Rule 3.14, Noxopharm Limited (ASX: NOX) wishes to advise its Registered Office and Principal Place of Business have changed, with immediate effect to:

**Registered Office:**

Level 5,  
126 Phillip Street,  
Sydney, NSW 2000

**Principal Place of Business:**

60 Linksley Avenue  
Glenhaven NSW 2156

**-ENDS-**

**About Noxopharm**

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation.

Its two innovative technology platforms – Chroma™ (oncology) and Sofra™ (inflammation and autoimmunity, including mRNA vaccine enhancement) – provide the basis for active development of a growing pipeline of new proprietary drugs.

Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: [noxopharm.com](http://noxopharm.com)

**Investor, Corporate & Media enquiries:**

Julian Elliott  
M: 0425 840 071  
E: [julian.elliott@noxopharm.com](mailto:julian.elliott@noxopharm.com)

**Company Secretary:**

David Franks  
T: +61 2 8072 1400  
E: [David.Franks@atomicgroup.com.au](mailto:David.Franks@atomicgroup.com.au)

*Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*

## **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.